Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for DIPG, DMG, or B7-H3-Positive Recurrent or Refractory Pediatric Central Nervous System Tumors

BrainChild-03

  • Condition(s): Atypical Teratoid/Rhabdoid Tumor, Brain Tumor, CNS Embryonal Tumors, CNS Germ Cell Tumors, Choroid Plexus Tumors, Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma (DMG), Ependymoma, Glioneuronal and Neuronal Tumors, High-Grade Glioma, Low-Grade Glioma, Medulloblastoma, Newly diagnosed, Pilocytic Astrocytoma, Recurrent and/or Refractory
  • Phase: I
  • Clinicaltrials.gov ID: NCT04185038

What is the goal of the study?

In this phase 1 clinical trial, Seattle Children's is testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors, including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). Researchers are working to answer these questions: -Is this T-cell therapy safe to give to children and young adults with recurrent or refractory CNS tumors, including DIPG and DMG? -What is the best dose of this therapy?

Who can participate in the study?

This study might be a good fit for children and young adults who: - Are ages 1 to 26 years old - Have recurrent or refractory CNS tumors, including DIPG and DMG Researchers use many other factors to decide whether or not a patient can take part in a study (called includion or exclusion criteria). The study team at Seattle Children's can explain what these factors mean for you or your child.

Study Team: